학술논문

Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma.
Document Type
Article
Source
Journal of Allergy & Clinical Immunology; 2022 Supplement, Vol. 149 Issue 2, pAB318-AB318, 1p
Subject
Language
ISSN
00916749